What are the pregnancy risks and recommended management for a woman with Sjögren’s syndrome?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 7, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Sjögren's Syndrome in Pregnancy: Risks and Management

Women with Sjögren's syndrome face increased pregnancy risks including preeclampsia, preterm delivery, intrauterine growth restriction, and most critically, congenital heart block in anti-Ro/SSA or anti-La/SSB positive mothers—requiring structured preconception counseling, hydroxychloroquine therapy, and intensive fetal cardiac surveillance.

Maternal and Fetal Risks

Maternal Complications

Women with Sjögren's syndrome experience significantly elevated risks compared to the general population 1:

  • Preeclampsia: 1.63-fold increased risk
  • Preterm delivery: 1.56-fold increased risk
  • Cesarean delivery: 1.29-fold increased risk
  • Premature rupture of membranes: 1.28-fold increased risk
  • Venous thromboembolism: 3.71-fold increased risk

However, recent prospective data from the GR2 study provides reassurance that overall adverse pregnancy outcomes in Sjögren's syndrome (9%) are not significantly different from the general population (7%) when properly managed 2.

Fetal and Neonatal Risks

The most concerning fetal complications include 1, 3:

  • Intrauterine growth restriction (IUGR): 3.0-fold increased risk
  • Congenital malformations: 3.26-fold increased risk
  • Congenital heart block (CHB): 0.7-2% risk in anti-Ro/SSA positive mothers, rising to higher rates with prior affected pregnancies
  • Small-for-gestational-age: Increased incidence
  • Neonatal lupus: Associated with anti-Ro/SSA and anti-La/SSB antibodies

Critical Risk Factors for Adverse Outcomes

Multivariate analysis identifies specific predictors requiring heightened surveillance 4, 2:

  • Antiphospholipid antibody positivity: 50% of adverse outcomes occurred in aPL-positive pregnancies versus 4% in aPL-negative
  • Anti-U1-RNP antibody positivity: 3.56-fold increased risk of adverse outcomes
  • Subchorionic hemorrhage: 7.65-fold increased risk
  • Advanced maternal age: Independent predictor (OR 1.40 per year)

Preconception Counseling and Risk Stratification

Essential Laboratory Testing

Test once before or early in pregnancy 5, 6:

  • Anti-Ro/SSA antibodies
  • Anti-La/SSB antibodies
  • Lupus anticoagulant (LAC)
  • Anticardiolipin antibodies (aCL) IgG/IgM
  • Anti-β2-glycoprotein I (aβ2GPI) IgG/IgM

Do not repeat these tests during pregnancy as they remain stable 5.

Timing of Conception

Strongly recommend delaying pregnancy until disease is quiescent or in low activity state 5. Active disease at conception increases risks of:

  • Disease flares during pregnancy (RR 2.1)
  • Hypertensive complications (OR 1.8)
  • Fetal loss and preterm delivery (OR 5.7 and 6.5 respectively) 6

Management During Pregnancy

Hydroxychloroquine: The Cornerstone of Therapy

All women with Sjögren's syndrome should take hydroxychloroquine during pregnancy 5, 6:

  • If already on HCQ: Strongly recommend continuing (Grade 1/B evidence)
  • If not on HCQ: Conditionally recommend starting if no contraindication (Grade 2/B evidence)
  • Dosing: 400 mg daily 7
  • Benefits: Reduces SLE flares, improves obstetrical outcomes, and may reduce anti-Ro/SSA antibody-mediated cardiac injury 6, 3

Low-Dose Aspirin

Start low-dose aspirin (81-100 mg daily) in women at risk for preeclampsia 5, 6:

  • Those with lupus nephritis
  • Those with positive antiphospholipid antibodies
  • Initiate preconceptionally or no later than 16 weeks gestation 6

Antiphospholipid Antibody-Positive Patients

For women with positive aPL 5, 6:

  • Obstetric APS: Low-dose aspirin + prophylactic heparin (Grade 1/A evidence)
  • Thrombotic APS: Low-dose aspirin + therapeutic heparin
  • Use LMWH over unfractionated heparin for practical reasons despite RCT evidence only for unfractionated heparin 6

Corticosteroids

Use prednisone only for acute, widespread disease flares 6:

  • Conditional recommendation (Grade 3/C)
  • Avoid routine prophylactic use due to maternal risks (infection, hypertension, weight gain, osteonecrosis) and fetal risks (IUGR, oligohydramnios, adrenal suppression) without demonstrated benefit 3
  • Exception: Short-course dexamethasone may be considered for first- or second-degree heart block detected on fetal echo 5, 7

Medications to Avoid

Absolutely contraindicated 6:

  • Mycophenolic acid
  • Cyclophosphamide
  • Leflunomide
  • Methotrexate

Fetal Surveillance Protocol

For Anti-Ro/SSA or Anti-La/SSB Positive Mothers

Implement intensive fetal cardiac monitoring 5, 6:

  1. Serial fetal echocardiography from 16-26 weeks gestation

    • Weekly frequency if history of previous child with CHB 5
    • Weekly to biweekly if no prior CHB 6
    • Monitor PR interval and AV conduction
  2. If abnormal findings detected:

    • First- or second-degree heart block: Brief course of dexamethasone 5, 7
    • Third-degree (complete) heart block: Recommend against dexamethasone as spontaneous reversal is rare 5
    • Against therapeutic heparin or IVIG for established complete block 5
  3. Supplementary surveillance:

    • Doppler ultrasonography in third trimester
    • Biometric parameters to screen for placental insufficiency and small-for-gestational-age fetuses 6

Cost-Effectiveness Caveat

The cost-effectiveness of intensive weekly/biweekly fetal echo surveillance in anti-Ro/La-positive women without prior CHB remains uncertain given the low 0.7-2% baseline risk 6. However, given the severity of complete CHB and lack of effective treatment once established, surveillance is still recommended.

Multidisciplinary Care Requirements

Essential team members 3, 8:

  • Maternal-fetal medicine specialist
  • Rheumatologist
  • Pediatric cardiologist (for fetal echo interpretation)
  • Neonatologist (for delivery planning)

Neonatal Considerations

For infants with in-utero exposure to maternal anti-Ro/SSA antibodies 5:

  • Consult pediatrician regarding timing of live vaccines
  • Monitor for neonatal lupus manifestations
  • ECG and echocardiography at birth if maternal antibodies present

Postpartum Management

  • Continue hydroxychloroquine
  • Consider low-dose corticosteroids (e.g., methylprednisolone 6 mg daily) for disease suppression 7
  • Thromboprophylaxis with LMWH for 4-6 weeks if aPL-positive
  • Monitor for disease flares (13% flare rate in prospective cohort) 2

Key Clinical Pitfalls

  1. Failing to test for anti-Ro/SSA and aPL antibodies preconceptionally: These determine surveillance intensity and treatment strategy
  2. Discontinuing hydroxychloroquine due to pregnancy concerns: HCQ is safe and beneficial—stopping increases flare risk
  3. Delaying aspirin initiation beyond 16 weeks: Reduces effectiveness for preeclampsia prevention
  4. Using prophylactic steroids routinely: No proven benefit and significant maternal-fetal risks
  5. Inadequate fetal cardiac surveillance in anti-Ro/SSA-positive mothers: Complete heart block requires early detection for any intervention attempt

Bottom line: Sjögren's syndrome pregnancies require proactive risk stratification, continuation of hydroxychloroquine, structured fetal cardiac surveillance for antibody-positive mothers, and multidisciplinary coordination—but with proper management, most women achieve successful pregnancy outcomes comparable to the general population.

References

Research

"An update on the approach to treatment of Sjogren's Disease in pregnancy".

The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians, 2024

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.